EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma

Kevin C Johnson, An-Chi Tien, Jun Jiang, James McNamara, Yu-Wei Chang, Chelsea Montgomery, Anita DeSantis, Leonel Elena-Sanchez, Yoko Fujita, Seongho Kim, Avishay Spitzer, Paul Gabriel und 10 weitere

Neuro-Oncology · 01.03.2026 · 28 (3) · 659-671

DOI: 10.1093/neuonc/noaf257 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, online erschienen am 08.11.2025. Verfasst von Kevin C Johnson und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Yale School of Medicine, New Haven. Hauptthemen laut MEDLINE: Glioma, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ben and Catherine Ivy Foundation, Barrow Neurological Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractAbstract Background Outcomes for adult patients with high-grade glioma (HGG) remain poor, necessitating new treatment strategies. Key challenges include poor drug penetration in the brain and malignant cell state plasticity. Phase 0 studies identify agents that achieve target modulation through pharmacologically relevant brain concentrations.

Methods

A Phase 0/1 clinical trial combined the 2 targeted inhibitors ribociclib (CDK4/6 inhibitor) and everolimus (mTOR inhibitor) in recurrent HGG patients, aiming to identify brain-penetrant combinations and assess their impact on malignant cell states. We enrolled 24 patients with recurrent HGG, characterized by CDKN2A/B deletion or CDK4/6 amplification, PTEN loss or PIK3CA mutations, and wildtype retinoblastoma protein (Rb). Tumors were evaluated for pharmacokinetics, pharmacodynamics, and single nucleus transcriptomics.

Results

Median unbound ribociclib concentrations in gadolinium non-enhancing tumor regions were significantly above the biochemical IC50 for CDK4/6 inhibition at 400 and 600 mg QD doses. Unbound everolimus concentrations were undetectable (<0.1 nM) in tumor regions across all dose levels. Ribociclib treatment was associated with significantly decreased Ki-67-positive cells. Single-nucleus RNA sequencing of 17 on-trial IDH-wildtype recurrences and 88 standard-of-care-treated recurrences showed a significantly lower fraction of cycling and neural progenitor-like malignant cell populations in ribociclib-everolimus-treated tumors. CDK4/6 inhibitor-directed malignant cell state shifts were validated using 3 patient-derived cell lines.

Conclusions

This trial underscores the value of integrating pharmacokinetics, pharmacodynamics, and single-nucleus transcriptomics in Phase 0/1 surgical studies to assess treatment effects, including malignant cell state shifts. Clini­calTrials.gov identifier: NCT03834740.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Brain NeoplasmsNeoplasm Recurrence, LocalTranscriptomeMTOR InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansAminopyridinesFemalePurinesMaleMiddle AgedAdultEverolimusTOR Serine-Threonine KinasesAgedNeoplasm GradingPrognosisBiomarkers, TumorFollow-Up Studies

Stichwörter der Autor:innen

CDK4glioblastomagliomaplasticityribociclibsingle celltargeted therapy

Substanzen

AminopyridinesCyclin-Dependent Kinase 4PurinesCyclin-Dependent Kinase 6ribociclibMTOR protein, humanCDK4 protein, humanCDK6 protein, humanEverolimusMTOR Inhibitors

Autor:innen und Institutionen

  • Department of Neurosurgery, Yale School of Medicine, New Haven.
  • Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix.
  • Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.J., S.K., J.L.).
  • Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot.
  • Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv.

ORCID-Profile: Roel G W Verhaak

Förderung

  • Ben and Catherine Ivy Foundation
  • Barrow Neurological Foundation
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Johnson, K. C., Tien, A. C., Jiang, J., McNamara, J., Chang, Y. W., Montgomery, C., DeSantis, A., Elena-Sanchez, L., Fujita, Y., Kim, S., Spitzer, A., Gabriel, P., Flynn, W. F., Courtois, E. T., Hong, A., Harmon, J., Umemura, Y., Tovmasyan, A., Li, J., …, & Sanai, N. (2026). Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma. Neuro-Oncology, 28(3), 659-671. https://doi.org/10.1093/neuonc/noaf257

Vancouver

Johnson KC, Tien AC, Jiang J, McNamara J, Chang YW, Montgomery C, et al. Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma. Neuro-Oncology. 2026;28(3):659-671. doi:10.1093/neuonc/noaf257

BibTeX
@article{Johnson2026,
  author = {Johnson, Kevin C and Tien, An-Chi and Jiang, Jun and McNamara, James and Chang, Yu-Wei and Montgomery, Chelsea and DeSantis, Anita and Elena-Sanchez, Leonel and Fujita, Yoko and Kim, Seongho and Spitzer, Avishay and Gabriel, Paul and Flynn, William F and Courtois, Elise T and Hong, Amy and Harmon, Jocelyn and Umemura, Yoshie and Tovmasyan, Artak and Li, Jing and Mehta, Shwetal and Verhaak, Roel G W and Sanai, Nader},
  title = {Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma},
  journal = {Neuro-Oncology},
  year = {2026},
  volume = {28},
  number = {3},
  pages = {659--671},
  doi = {10.1093/neuonc/noaf257}
}
Kostenlos starten →